# Chrysalis-2 (NCT04077463)

> A Study of Lazertinib as Monotherapy or in Combination With Amivantamab in Participants With Advanced Non-small Cell Lung Cancer

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT04077463
- Phase: PHASE1
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: Janssen Research & Development, LLC
- Conditions: Carcinoma, Non-Small-Cell Lung
- Interventions: Lazertinib; Amivantamab; Carboplatin; Pemetrexed
- Enrollment: 701
- Primary outcome: Percentage of Participants with Dose-Limiting Toxicity (DLT) (Phase 1)
- Primary outcome: Percentage of Participants with Dose-Limiting Toxicity (DLT) (Phase 1b)
- Primary outcome: Overall Response Rate (ORR) (Phase 1b Expansion Cohorts A-D)
- Primary outcome: Number of Participants with Adverse Events (AEs) as a Measure of Safety and Tolerability (Phase 1b Expansion Cohorts A-E)
- Primary outcome: Percentage of Participants with DLT (Phase 1b combination Lazertinib, Amivantamab, Platinum-doublet chemotherapy [LACP])
- Primary outcome: Number of Participants with AEs as a Measure of Safety and Tolerability (Phase 1b combination LACP)
- Primary outcome: Overall Response Rate (ORR) per RECIST version 1.1 (v1.1) with NGS Analysis of Circulating Tumor ctDNA, IHC Analysis of EGFR and MET Expression (Phase 1b Expansion Cohort D)
- Primary outcome: ORR Among Participants with MET3+ Staining on Greater Than or Equal to (>=)25 Percent (%) of Tumor Cells (Phase 1b Expansion Cohorts E and F)
- Primary outcome: Duration of Response (DOR) Among Participants with MET3+ Staining on >=25% of Tumor Cells (Phase 1b Expansion Cohorts E and F)
- Primary outcome: Clinical Benefit Rate (CBR) Among Participants with MET3+ Staining on >=25% of Tumor Cells (Phase 1b Expansion Cohorts E and F)

## Commentary we found

- X threads: 69
- YouTube: 13
- Podcasts: 11
- X videos: 2

## Order

Deep, $1,950, price fixed at order: https://www.erudio.com/contact?report=chrysalis-2-nct04077463

## Free build

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT04077463", "email": "<work email>"}; the inbox owner confirms by the emailed link.